Tyr451
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr451  -  AGPS (human)

Site Information
LDGLKKFyITKFkGF   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1885079904

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 )
Disease tissue studied:
prostate cancer ( 1 )
Relevant cell line - cell type - tissue:
DU 145 (prostate cell) ( 1 )

Upstream Regulation
Putative in vivo kinases:
TrkA (human) ( 1 )
Treatments:
Larotrectinib ( 1 )

Downstream Regulation
Effects of modification on AGPS:
protein degradation ( 1 ) , ubiquitination ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 )
Induce interaction with:
MDM2 (human) ( 1 )

References 

1

Zhang Y, et al. (2024) TrkA promotes MDM2-mediated AGPS ubiquitination and degradation to trigger prostate cancer progression. J Exp Clin Cancer Res 43, 16
38200609   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.